Key result
Percutaneous pediatric ASD closure with GCO links to sustained P wave and QTc dispersion improvements.
Why the study?
The GORE CARDIOFORM septal occluder has theoretical advantages due to softness and compliance, but short- and medium-term electrocardiographic changes after pediatric percutaneous ASD closure required evaluation.
Does percutaneous ASD closure with the GCO device improve electrocardiographic parameters in pediatric patients?
Observational (n=39)
Does percutaneous ASD closure with the GCO device improve electrocardiographic parameters in pediatric patients?
Percutaneous ASD closure with the GCO device in pediatric patients leads to rapid and sustained improvements in electrical homogeneity and right heart remodeling.
Answers are grounded in this paper and cite their sources.
May support electrical remodeling after pediatric ASD closure with GCO; leaves open randomized confirmation of device-specific effects.
Background and aim: The GORE® CARDIOFORM (GCO) septal occluder is an atrial septal defect/patent foramen ovale closure device with theoretical advantages over other commercialized devices thanks to its softness and anatomical compliance. Our aim was to evaluate the short- and medium-term electrocardiographic changes after percutaneous ASD closure with GCO in a pediatric population. Methods: We enrolled 39 patients with isolated ASD submitted to trans-catheter closure from January 2020 to June 2021. ECG was performed before, at 24 h and 6 months after the procedure. P wave dispersion, QTc and QTc dispersion were calculated. ECG Holter was recorded at 6 months after implantation. Results: Patients’ age and body surface area (BSA) were 8.2 ± 4.2 years and 1.0 ± 0.3 m2 respectively. At the baseline, mean P wave dispersion was 40 ± 15 msec and decreased at 24 h (p < 0.002), without any further change at 6 months. At 24 h, PR conduction and QTc dispersion significantly improved (p = 0.018 and p < 0.02 respectively), while the absolute QTc value considerably improved after 6 months. During mid-term follow-up, QTc dispersion remained stable without a significant change in PR conduction. The baseline cardiac frequency was 88.6 ± 12.6 bpm, followed by a slight reduction at 24 h, with a further amelioration at 6 months after the procedure (87.3 ± 14.2, p = 0.9 and 81.0 ± 12.7, p = 0.009, respectively). After device deployment, two patients developed transient, self-limited junctional rhythm. One of them needed a short course of Flecainide for atrial ectopic tachycardia. No tachy/brady-arrhythmias were recorded at the 6-month follow-up. ASD closure resulted in a marked decrease in right heart volumes and diameters at 6 months after percutaneous closure. Conclusions: Percutaneous ASD closure with the GCO device results in significant, sudden improvement of intra-atrial, atrio-ventricular and intraventricular electrical homogeneity. This benefit persists unaltered over a medium-term follow-up. These electrical changes are associated with a documented positive right heart volumetric remodeling at mid-term follow-up.
No takes yet. Share an insight, caveat, or question.
Fumanelli et al. (2023) conducted an observational in Isolated atrial septal defect (ASD) (n=39). Percutaneous ASD closure with GORE CARDIOFORM (GCO) septal occluder was evaluated on Short- and medium-term electrocardiographic changes (P wave dispersion, QTc, QTc dispersion) (p=<0.002). Percutaneous ASD closure with the GCO device in pediatric patients significantly improved P wave dispersion at 24 hours (p<0.002) and QTc dispersion (p<0.02), with benefits persisting at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: